351
Participants
Start Date
September 18, 2017
Primary Completion Date
May 3, 2018
Study Completion Date
April 24, 2019
Placebo
Vehicle Ointment was used in participants with Clinically typical AK on the face or scalp.
KX2-391 Ointment 1%
The experimental drug, KX2-391 Ointment 1% was used in participants with Clinically typical AK on the face or scalp.
Mount Sinai Beth Israel, New York
Skin Search of Rochester, Inc., Rochester
PMG Research of Winston-Salem,LLC, Winston-Salem
PMG Research of Cary, Cary
OnSite Clinical Solutions, LLC, Charlotte
Synexus US, Greer
Leavitt Medical Associates of Florida d/b/a Ameriderm Research, Ormond Beach
Clinical Research of South Florida, Coral Gables
Skin care Research, Inc, Boca Raton
Olympian Clinical Research, Clearwater
Coastal Clinical Research, Inc., Mobile
CTI Clinical Research Center, Cincinnati
The Indiana Clinical Trials Center, Plainfield
Deaconess Clinic Downtown, Evansville
Minnesota Clinical Study Center, Fridley
Arlington Dermatology, Arlington Heights
Skin Specialists PC, Omaha
DelRicht Research, New Orleans
Center for Clinical Studies, Webster
J&S Studies, Inc., College Station
Austin Institute for Clinical Research, Inc., Pflugerville
Western States Clincial Research, Inc., Wheat Ridge
Dermatology Research Center, Inc., Salt Lake City
Advanced Research Associates, Glendale
Academic Dermatology Associates, Albuquerque
JDR Dermatology Research, Las Vegas
Contour Dermatology, Rancho Mirage
Center For Dermatology Clinical Research, Fremont
ActivMed Practices & Research, Inc., Beverly
Psoriasis Treatment Center of Central New Jersey, East Windsor
Lead Sponsor
Collaborators (1)
Athenex, Inc.
INDUSTRY
Almirall, S.A.
INDUSTRY